Company intelligence / Profile preview

LiberoThera

Ownership: Private
Employees: ~9
Development stage: Other

Overview

LiberoThera is a Japanese biotech company specializing in innovative drug discovery targeting membrane proteins using proprietary cell-free expression systems and unnatural amino acid incorporation. Its lead pipeline asset is a monoclonal antibody targeting CCR8 for solid tumors, currently at the discovery stage. The company also offers drug discovery services leveraging its platform technologies. As of early 2025, there are no clinical results or approved drugs reported.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeCell-free membrane protein preparation technology
Industry: Biotech

Beyond the preview

Go deeper on LiberoThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiberoThera.

Explore the full profile